• ANGLE
  • ANGLE

    ANGLE is a liquid biopsy company with patent protected platforms include the Parsortix® circulating tumor cell (CTC) enrichment technology and the HyCEADTM Ziplex® platform for cost effective, highly multiplexed analysis of nucleic acids and proteins. The Parsortix® system enables a liquid biopsy (a simple blood draw) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). FDA clearance is in process for the United States. ANGLE is seeking to be the first ever FDA cleared CTC harvesting system. The HyCEADTM Ziplex® platform is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. The system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests. Using the Parsortix and HyCEAD Ziplex systems, ANGLE has already undertaken two separate 200 subject clinical studies to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (ROC-AUC) of 95.1%. The assay is currently in the process of a 200 patient clinical verification study.


    Lara Stevanato, PhD

    Product Support Lead

    10 Nugent rd, Surrey Research Park

    Guildford

    GU2 7AF

    United Kingdom

    L.Stevanato@angleplc.com


    Michael O’Brien

    Business Development Director

    10 Nugent rd, Surrey Research Park,

    Guildford

    GU2 7AF

    United Kingdom

    M.OBrien@angleplc.com

  • Cancer typesSolid tumor (e.g. breast, ovarian/pelvic mass, lung, prostate, melanoma, colorectal cancer)
    Clinical application“ANGLE has two (currently RUO) applications for:

    1. Harvesting circulating tumour cells (CTCs) from peripheral blood of patients diagnosed with metastatic breast cancer. Harvested CTCs can be used for subsequent downstream
    applications.

    2. Aiding the assessment of the likelihood of ovarian malignancy in women who present with a suspicious pelvic mass, prior to surgical intervention or other patient management decisions.”
    Liquid Biopsy sourceBlood
    Technologies available for liquid biopsyParsortix® and HyCEAD Ziplex® systems
    Articles related to the Parsortix® technologyKoch C, Joosse SA, , Schneegans S,y , Wilken OJW, Janning M, Loreth D, Müller V, Prieske K, Banys-Paluchowski M, Horst LJ, Loges S, Peine S, Wikman H, Gorges TM and Pantel K. Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. Cancers. 2020; 12: 442.

    Reinhardt F, Franken A, Meier-Stiegen F, Driemel C, Stoecklein NH , Fischer JC, Niederacher D, Ruckhaeberle E, Fehm T, and Neubauer H. Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance. Cancers. 2019; 11: 903

    Janning M, Kobus F, Babayan A, Wikman H , Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O’Flaherty L, Hille C, Joosse SA , Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K and Loges S. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitor. Cancers. 2019; 11: 835

    Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, Beisel C, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Beerenwinkel N, Aceto N. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019; 566; 553–557.

    Miller MG, Robinson PS, Wagner C, O'Shannessy DJ. The Parsortix™ Cell Separation System-A Versatile Liquid Biopsy Platform. Cytometry A. 2018; 93 (12): 1234-1239
  • Invitek
  • Invitek
    Invitek

    InviGenius PlUS 2
    InviGenius Plus 2

    Invitek Molecular develops and commercializes tailor-made nucleic acid purification solutions that enable manual and automated DNA/RNA extraction from virtually any sample material. We provide customized development and contract manufacturing services to in-vitro diagnostics companies all over the world. With more than 20 years of experience, our solutions cover all challenges from the idea up to the realization of a marketable product according to CE-IVD. Invitek Molecular is committed to developing products for state-of-the-art nucleic acid extraction used in oncology applications. Our extraction kits for liquid biopsy and pathology enable a reliable and reproducible application of cell-free circulating DNA and genomic DNA used in NGS detection systems. With our fully automated solutions, you can automate your workflows with just short hands-on time.

  • Thomas Matthes

    CEO

    Invitek Molecular GmbH
    Robert-Rössle-Str. 10
    13125 Berlin
    Germany

    thomas.matthes@invitek-molecular.com


    Dr. Andrea Ockhardt

    Project Manager

    Invitek Molecular GmbH
    Robert-Rössle-Str. 10
    13125 Berlin
    Germany

    andrea.ockhardt@invitek-molecular.com

  • Cancer typessolid tumors
    Clinical applicationcirculating cell-free DNA extraction for NGS applications
    Liquid Biopsy Sourceplasma, serum, urine
    Technologies available for Liquid Biopsyfully automated cell-free DNA extraction using magnetic beads on the InviGenius® PLUS platform